Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
Sign Up to like & getrecommendations! Published in 2022 at "The Lancet"
DOI: 10.1016/s0140-6736(21)02225-x
Abstract: BACKGROUND Hereditary angioedema is associated with dysregulation of the kallikrein-kinin system. Factor XII (FXII) is a key initiator of the kallikrein-kinin system, which produces bradykinin, a central mediator of angioedema. Garadacimab (CSL Behring) is a… read more here.
Keywords: placebo; treatment; factor xii; hereditary angioedema ... See more keywords